Raouf El Cheikh

Abstract 1820: Pharmacokinetic-tumor growth inhibition modeling of raludotatug deruxtecan (R-DXd) to support phase 3 dose selection in platinum-resistant ovarian cancer (PROC).

YoungJun Yoo, Kevin Koloskoff, Sandra Re, Izna Ali et autres

Abstract Background: R-DXd is a novel cadherin 6 (CDH6)-directed antibody-drug conjugate (ADC) under clinical investigation. In ongoing Phase 1 DS6000-A-U101 (NCT04707248) and Phase 2/3 REJOICE-Ovarian01 (NCT06161025) studies, preliminary data showed promising results in patients with platinum-resistant ovarian cancer (PROC). To support dose …

us, de (code pays fourni par la source)

Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer

Mitchell J. Elliott, Jaeyoon John Kim, Aizhen Dou, Jesús Fuentes‐Antrás et autres

BACKGROUND: The detection of circulating tumor DNA (ctDNA) after curative-intent therapy, referred to as molecular/minimal residual disease (MRD), is prognostic of disease recurrence in early-stage breast cancer (EBC). Tumor-agnostic approaches that rely on mutation-based assessment in fixed panels of common cancer driver …

ca, us, es (code pays fourni par la source)

Biological determinants of immune exclusion in non-small cell lung cancer: An analysis of the precision medicine BIP study.

Jean‐Philippe Guégan, Florent Peyraud, Christophe Rey, Sophie Cousin et autres

2636 Background: Immune exclusion has been associated with resistance to immunotherapy in NSCLC. However, its biological determinants remain largely unknown. Instead of relying on preclinical models, high-throughput profiling of patient samples using spatial transcriptomics (ST) and multiplex immunofluorescence (m-IF) offers a powerful …

fr, us, ca (code pays fourni par la source)

310P Longitudinal evaluation of circulating tumour DNA in early breast cancer using a plasma-only methylation-based assay

Mitchell J. Elliott, Jesús Fuentes‐Antrás, Aizhen Dou, Zachary William Neil Veitch et autres

ca, us (code pays fourni par la source)

Data from Implication of the Autologous Immune System in BCR–ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib

Geoffrey D. Clapp, Thomas Lepoutre, Raouf El Cheikh, Samuel Bernard et autres

Abstract Imatinib and other tyrosine kinase inhibitors (TKI) have improved treatment of chronic myelogenous leukemia (CML); however, most patients are not cured. Deeper mechanistic understanding may improve TKI combination therapies to better control the residual leukemic cell population. In analyzing our patients' …

Supplementary Tables 1 - 2, Figure 1 from Implication of the Autologous Immune System in BCR–ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib

Geoffrey D. Clapp, Thomas Lepoutre, Raouf El Cheikh, Samuel Bernard et autres

Table S1:Universal parameters estimates. Table S2: Patient-specific parameter estimates. Figure S1: Comparison of the model with and without an autologous immune response

Data from Implication of the Autologous Immune System in BCR–ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib

Geoffrey D. Clapp, Thomas Lepoutre, Raouf El Cheikh, Samuel Bernard et autres

Abstract Imatinib and other tyrosine kinase inhibitors (TKI) have improved treatment of chronic myelogenous leukemia (CML); however, most patients are not cured. Deeper mechanistic understanding may improve TKI combination therapies to better control the residual leukemic cell population. In analyzing our patients' …

Supplementary Tables 1 - 2, Figure 1 from Implication of the Autologous Immune System in BCR–ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib

Geoffrey D. Clapp, Thomas Lepoutre, Raouf El Cheikh, Samuel Bernard et autres

Table S1:Universal parameters estimates. Table S2: Patient-specific parameter estimates. Figure S1: Comparison of the model with and without an autologous immune response

Optimization of trabectedin temporal protocol using mathematical PK/PD modeling.

Maeva Andriantsoa, Raouf El Cheikh, Diane Charlotte Imbs, Raphaël Serre et autres

e23553 Background: Trabectedin (ET-743, Yondelis) is an antineoplastic agent indicated for the treatment of advanced soft tissue sarcomas (STS). Despite its efficacy, Trabectedin induces severe toxic side effects, especially neutropenia. In clinical settings, this leads to empirical dosing adjustments that disrupt the …

fr (code pays fourni par la source)

Modélisation mathématique dans un essai clinique de phase 1 : application dans le traitement des cancers bronchiques non à petites cellules et des mésothéliomes avancés, par vinorelbine orale, selon un schéma métronomique

Mathieu Barbolosi, D Imbs, Pascale Tomasini, Laurent Greillier et autres

fr (code pays fourni par la source)

Meningioma growth dynamics assessed by radiocarbon retrospective birth dating

Hagen B. Huttner, Olaf Bergmann, Mehran Salehpour, Raouf El Cheikh et autres

It is not known how long it takes from the initial neoplastic transformation of a cell to the detection of a tumor, which would be valuable for understanding tumor growth dynamics. Meningiomas show a broad histological, genetic and clinical spectrum, are usually …

se, de, fr (code pays fourni par la source)

Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non‐Small Cell Lung Carcinoma

D Imbs, Raouf El Cheikh, Arnaud Boyer, Joseph Ciccolini et autres

Concomitant administration of bevacizumab and pemetrexed-cisplatin is a common treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). Vascular normalization following bevacizumab administration may transiently enhance drug delivery, suggesting improved efficacy with sequential administration. To investigate optimal scheduling, we conducted a study …

fr (code pays fourni par la source)